These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 32891697)

  • 1. Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?
    Ferron PJ; Gicquel T; Mégarbane B; Clément B; Fromenty B
    Biochimie; 2020 Dec; 179():266-274. PubMed ID: 32891697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.
    Bessone F; Dirchwolf M; Rodil MA; Razori MV; Roma MG
    Aliment Pharmacol Ther; 2018 Nov; 48(9):892-913. PubMed ID: 30194708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease.
    Allard J; Le Guillou D; Begriche K; Fromenty B
    Adv Pharmacol; 2019; 85():75-107. PubMed ID: 31307592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management.
    Xu Y; Yang X; Bian H; Xia M
    Lipids Health Dis; 2021 Oct; 20(1):126. PubMed ID: 34602072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infections at the nexus of metabolic-associated fatty liver disease.
    Boeckmans J; Rombaut M; Demuyser T; Declerck B; Piérard D; Rogiers V; De Kock J; Waumans L; Magerman K; Cartuyvels R; Rummens JL; Rodrigues RM; Vanhaecke T
    Arch Toxicol; 2021 Jul; 95(7):2235-2253. PubMed ID: 34027561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.
    Vasques-Monteiro IML; Souza-Mello V
    World J Gastroenterol; 2021 Apr; 27(16):1738-1750. PubMed ID: 33967554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019.
    Vázquez-Medina MU; Cerda-Reyes E; Galeana-Pavón A; López-Luna CE; Ramírez-Portillo PM; Ibañez-Cervantes G; Torres-Vázquez J; Vargas-De-León C
    Hepatol Commun; 2022 Aug; 6(8):2000-2010. PubMed ID: 35438253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19.
    Cordeiro A; Ribamar A; Ramalho A
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101807. PubMed ID: 34543756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.
    Massart J; Begriche K; Moreau C; Fromenty B
    J Clin Transl Res; 2017 Feb; 3(Suppl 1):212-232. PubMed ID: 28691103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease.
    Massart J; Begriche K; Corlu A; Fromenty B
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.
    Jeeyavudeen MS; Chaudhari R; Pappachan JM; Fouda S
    World J Gastroenterol; 2023 Jan; 29(3):487-502. PubMed ID: 36688018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of metabolic dysfunction associated fatty liver disease in COVID-19.
    Chakraborty R; Sharma D; Kapoor DU; Dwivedi A; Khabiya R; Sen S
    World J Clin Cases; 2023 Feb; 11(6):1275-1286. PubMed ID: 36926128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic Diagnosis of Nonalcoholic Fatty Liver Disease.
    Lai J; Wang HL; Zhang X; Wang H; Liu X
    Arch Pathol Lab Med; 2022 Aug; 146(8):940-946. PubMed ID: 34871361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease.
    Michaut A; Moreau C; Robin MA; Fromenty B
    Liver Int; 2014 Aug; 34(7):e171-9. PubMed ID: 24575957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic performance of an index based on lactic dehydrogenase and transaminases for patients with liver steatosis and COVID-19.
    Macías-Rodríguez RU; Solís-Ortega AA; Ornelas-Arroyo VJ; Ruiz-Margáin A; González-Huezo MS; Urdiales-Morán NA; Román-Calleja BM; Mayorquín-Aguilar JM; González-Regueiro JA; Campos-Murguía A; Toledo-Coronado IV; Chapa-Ibargüengoitia M; Valencia-Peña B; Martínez-Cabrera CF; Flores-García NC
    World J Gastroenterol; 2022 Oct; 28(37):5444-5456. PubMed ID: 36312835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease.
    Dai YN; Xu CF; Pan HY; Huang HJ; Chen MJ; Li YM; Yu CH
    World J Clin Cases; 2022 May; 10(13):4097-4109. PubMed ID: 35665109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19, adaptative immune response and metabolic-associated liver disease.
    Miele L; Napodano C; Cesario A; De Magistris A; Pocino K; Basile U; Rapaccini GL; Gasbarrini A; Grieco A
    Liver Int; 2021 Nov; 41(11):2560-2577. PubMed ID: 34555255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.
    Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models.
    Zhao QY; Ge LH; Zhang K; Chen HF; Zhan XX; Yang Y; Dang QL; Zheng Y; Zhou HB; Lyu JX; Fang HZ
    Zool Res; 2020 Sep; 41(5):539-551. PubMed ID: 32786176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic-associated fatty liver disease and lipoprotein metabolism.
    Heeren J; Scheja L
    Mol Metab; 2021 Aug; 50():101238. PubMed ID: 33892169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.